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Abstract We investigated the e¡ect of 10 WM clozapine on the
activity of glycogen synthase kinase-3L (GSK-3L) and its up-
stream and downstream molecules in SH-SY5Y human neuro-
blastoma cells. Clozapine activates both Akt- and Dvl-mediated
phosphorylation of GSK-3L through phosphorylation at Ser9,
and increased total cellular and intranuclear levels of L-catenin.
Pretreatment with the speci¢c inhibitor of the phosphatidylino-
sitol 3-kinase (PI3K)-Akt pathway, LY294002 (20 WM), pre-
vented the phosphorylation of Akt but did not a¡ect the phos-
phorylation of GSK-3L. These results suggest that clozapine
regulates the phosphorylation of GSK-3L through Wnt signal
pathways involving Dvl upstream but not through the PI3K-Akt
pathway in SH-SY5Y cells.
4 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Clozapine is a representative of ‘atypical’ antipsychotic
agents and its major indication is treatment-resistant schizo-
phrenia [1,2]. However, it can also be successfully used for the
treatment of treatment-resistant bipolar disorder [1] and it is
proposed that clozapine also has considerable mood-stabiliz-
ing e¡ects [3]. Glycogen synthase kinase-3 (GSK-3) is com-
monly a¡ected by di¡erent kinds of mood stabilizers such as
lithium and valproate. The inhibition of GSK-3 by these
drugs could be responsible for their neuroprotective properties
or their therapeutic e¡ects [4^6].
GSK-3 works in two major contexts [7]. The one is receptor
tyrosine kinase-mediated signaling. In this context, the upper-
most signaling event is receptor binding of growth factors like
insulin. Thus, autophosphorylated receptor activates the phos-
phatidylinositol 3-kinase (PI3K), and the cascade of signaling
event leading to the activation of protein kinase B (Akt/PKB).
Akt phosphorylates GSK-3 and GSK-3 phosphorylated on its
Ser9 residue loses its enzymatic activity [8]. This results in the
decreased phosphorylation of its substrate, glycogen synthase.
Glycogen synthase is subsequently activated as a result of the
decreased phosphorylation.
The other major context of GSK-3 signaling is mediated via
the seven transmembrane receptor Frizzled, and the extracel-
lular signal Wnt. Wnt-mediated GSK-3 signaling is com-
pletely di¡erent from that mediated by insulin. In this system,
GSK-3 works within a multimolecular complex composed of
several molecules including Axin, APC, and L-catenin [9,10].
Without upstream signal, dephosphorylated GSK-3 is cata-
lytically active and phosphorylates its downstream molecule
L-catenin. When Wnt binds to Frizzled, the adapter protein
Dishevelled (Dvl) is phosphorylated, and this leads to the
phosphorylation-deactivation of GSK-3 [11]. Through this de-
activation, the phosphorylation status of L-catenin is de-
creased, which results in release of L-catenin from the com-
plex. The released L-catenin enters into the nucleus, where it
binds to the T-cell factor family transcription factor (also
known as the lymphoid-enhancer factor family) and induces
the transcription of target genes [12].
In this study, we examined the e¡ect of clozapine on the
signaling cascade related to GSK-3. Since other mood-stabi-
lizing agents such as lithium and valproate have similar e¡ects
on GSK-3 [4,5], we speculated that clozapine may also a¡ect
the signaling system mediated by GSK-3 in a similar fashion.
2. Materials and methods
2.1. Cell culture, serum starvation and drug treatment
The human neuroblastoma cell line SH-SY5Y (ATCC) was grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM, Gibco BRL) sup-
plemented with 10% (v/v) fetal bovine serum and 1% penicillin^strep-
tomycin (Gibco BRL) in a 37‡C humidi¢ed incubator with 5% CO2.
For serum starvation, cells cultured in the complete growth medium
were changed to serum-free DMEM and incubated for 24 h. Cloza-
pine (Tocris) was dissolved in dimethylsulfoxide (DMSO) at a con-
centration of 100 WM. To block the activity of PI3K, the cells were
pretreated with LY294002 (Sigma) at a concentration of 20 WM, 1 h
before clozapine treatment. For in vitro dephosphorylation of protein,
lysates were treated with 50 U of alkaline phosphatase (Sigma) at
30‡C for 30 min and diluted with an equal volume of cell lysis bu¡er.
2.2. Electrophoresis and Western blotting
Cells were washed in ice-cold phosphate-bu¡ered saline (PBS) and
lysed in RIPA(+) (0.1% sodium dodecyl sulfate (SDS), 1.0% Triton X-
100 and 1.0% deoxycholate in PBS) containing 1 mM dithiothreitol
(DTT), 1% protease inhibitor cocktail (Sigma), 1 mM phenylmethyl-
sulfonyl £uoride (PMSF), 1 mM Na3VO4, 1 mM NaF and 1 mM L-
glycerophosphate at 4‡C for 15 min. Proteins were separated by SDS^
polyacrylamide gel electrophoresis (PAGE). Immunoblotting with pri-
mary antibodies including anti-phospho-GSK-3L (Ser9), anti-GSK-
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3L, anti-phospho-Akt, anti-Akt, anti-phospho-L-catenin (Ser33/37/
Thr41) (Cell Signaling Technology), anti-phospho-GSK-3L (Tyr216)
(Upstate Biotechnology), anti-poly (ADP-ribose) polymerase (PARP),
anti-caspase-3 (Santa Cruz) and anti-L-catenin (BD Transduction
Laboratories) was done. Immunoblotting was performed as described
[13].
2.3. Preparation of nuclear extract
SH-SY5Y cells were washed with PBS three times, resuspended in
500 Wl of ice-cold bu¡er A (10 mM HEPES-KOH, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and incubated on
ice for 15 min. Then 0.1% Nonidet P-40 (NP-40) was added to the cell
extract, incubated on ice for 5 min and centrifuged at 12 000 rpm for
30 s at 4‡C. Nuclear proteins were extracted by addition of 100 Wl of
bu¡er B (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5
mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, protease
inhibitor cocktail) for 30 min at 4‡C with occasional vortexing. After
centrifugation at 13 000 rpm for 5 min at 4‡C, supernatants were
collected and stored at 370‡C.
2.4. Immuno£uorescence staining
SH-SY5Y cells were grown on round coverslips in multiwell culture
plates and exposed to clozapine (10 WM) for indicated times. For L-
catenin staining, the permeabilized cells were incubated with anti-L-
catenin antibody (BD Transduction Laboratories) for 3 h at room
temperature. After washing, the cells were stained with £uorescein
isothiocyanate (FITC)-conjugated secondary antibody for 1 h and
mounted on slide glasses with mounting medium.
2.5. DAPI staining
SH-SY5Y cells grown as described above were exposed to clozapine
for the indicated times. The resulting cells were stained with 4P,6P-
diamidino-2-phenylindole (DAPI) (0.4 Wl/ml; Sigma) for 5 min,
washed, and then examined with a £uorescence microscope. Apopto-
tic cells were scored on the basis of the presence of highly condensed
or fragmented nuclei.
2.6. MTT assay
SH-SY5Y cells were seeded in a 96-well tissue culture plate and
incubated for 24 h. After treatment with clozapine, cells were incuba-
ted in yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) solution (0.5 mg/ml). After incubation, the medium con-
taining MTT solution was removed and each well received 100 Wl
DMSO that solubilized the preformed purple formazan salt crystals.
The solubilized formazan product was spectrophotometrically quanti-
¢ed using an ELISA reader.
2.7. Analysis of apoptotic cell population by FACS
Exponentially growing cells were treated with clozapine, collected,
and ¢xed with chilled 70% EtOH. Ten thousand cells stained with
propidium iodide (PI) were analyzed on a £uorescence-activated cell
sorter (FACSCalibur; Becton Dickinson), and the resulting DNA
histograms were converted to proportions of each cell cycle phase
by the ModiFit LT software (Becton Dickinson).
3. Results
3.1. E¡ect of clozapine on cell survival
We observed the e¡ect of clozapine on cell survival and
death. When we treated the cells with increasing concentra-
tions of clozapine, cell death occurred at the concentration of
30 WM or more (Fig. 1A). The doubling time was also some-
what retarded with concentrations of 30 WM or more of clo-
zapine (data not shown) and ensuing experiments were done
using 10 WM of clozapine. There were no changes (Fig. 1B) in
the cellular morphology and DAPI staining also showed in-
tact nuclei until 10 WM clozapine (Fig. 1C). There was also no
cleavage of PARP and pro-caspase-3 (Fig. 1D), indicating no
apoptosis at this concentration. FACS results also showed
that there was no increase in the fragmented DNA (Fig.
1E). In contrast, when the cells were exposed to a pro-apo-
ptotic control stimulus (heat shock up to 45‡C for 90 min)
and observed 48 h later, the results were positive for all apo-
ptotic screening tests.
3.2. E¡ect of clozapine on GSK-3L phosphorylation
GSK-3L was constitutively phosphorylated below 10% se-
rum content. So we reduced the concentration of serum to
Fig. 1. A: SH-SY5Y cells were treated with 1^100 WM clozapine for
72 h and cell viability was measured by the MTT assay. Data are
shown as the means of triplicate samples and represent the viability
of cells compared with untreated cells. B: Serum-starved (SS) SH-
SY5Y cells were exposed to 10 WM clozapine (Clo) for 24 h. Origi-
nal magni¢cation 200U. C: Serum-starved SH-SY5Y cells exposed
to either 10 WM clozapine for 24 h or heat shock (HS) at 45‡C for
90 min and recovered at 37‡C for 48 h and the cellular proteins
were analyzed by SDS^PAGE and Western blotting with anti-
PARP and anti-pro-caspase-3. D: Serum-starved SH-SY5Y cells
were exposed to 10 WM clozapine for 24 h. The cells were stained
with DAPI and the nuclei were observed under a £uorescence
microscope. E: Serum-starved SH-SY5Y cells were exposed to 10
WM clozapine or heat shock for the indicated times and stained
with PI and analyzed by FACS analysis.
FEBS 28096 17-2-04 Cyaan Magenta Geel Zwart
U.G. Kang et al./FEBS Letters 560 (2004) 115^119116
0%, i.e. serum-free medium (referred to as ‘serum starvation’
in this article) to single out the e¡ect of clozapine. Despite this
low serum concentration, there was no remarkable cell death
and this condition passed the entire apoptotic screening test
described above, until the very last time point observed.
Under serum-starved condition, the phosphorylation of
GSK-3L was reduced compared with 10% serum condition.
Adding clozapine (10 WM) to this serum-starved condition
increased the phosphorylation of GSK-3L within 10 min.
And the phosphorylation was maintained over 24 h (Fig. 2).
3.3. Upstream event of GSK-3L phosphorylation
The phosphorylation of GSK-3L can be regulated by two
major upstream pathways. One is the Akt pathway and the
other is the Wnt signaling pathway mediated by increased
phosphorylation of the adapter protein, Dvl. Using speci¢c
antibody against phosphorylated Akt, we demonstrated that
Akt is also phosphorylated by clozapine at similar time points
as the phosphorylation of GSK-3L (Fig. 3A). The phosphor-
ylation of Dvl was also demonstrated using band mobility
shift in Western blot analysis (Fig. 3B). After treatment of
the cell lysate with alkaline phosphatase, the shifted Dvl
band disappeared along with the phosphorylated band of
GSK-3L and Akt. Since a speci¢c inhibitor of the PI3K-Akt
pathway was available, we pretreated the cells with LY294002
(20 WM) and then with clozapine. As expected, LY294002
pretreatment abolished the phosphorylation of Akt. However,
the phosphorylation of GSK-3L was not changed by
LY294002 pretreatment (Fig. 4). This suggested indirectly
that the Wnt pathway is more critical for GSK-3L phosphor-
ylation under the clozapine paradigm.
3.4. Downstream pathway of GSK-3L
Since the Wnt pathway seemed more critical, we observed
the downstream pathway associated with Wnt signaling, i.e. L-
catenin. First, we examined changes in L-catenin phosphory-
lation in response to clozapine. Treatment with clozapine re-
sulted in accumulation of L-catenin through dephosphoryla-
tion at Ser33/37/Thr41 (Fig. 5A). Next, we observed the
changes in the amount of L-catenin. Clozapine treatment in-
creased the amount of L-catenin (Fig. 5B). We fractionated
the cell lysate into nuclear and cytoplasmic portions, and de-
termined the amount of L-catenin separately. There was clear
evidence that the nuclear content of L-catenin was selectively
increased (Fig. 5B). Then we demonstrated this nuclear mi-
gration by immuno£uorescence staining. As shown in Fig. 5C,
under the control condition, the L-catenin was concentrated at
the cell^cell junction. There was also di¡use cytoplasmic stain-
ing, save the nucleus. When the cells were treated with cloza-
pine, the number of cells showing nuclear staining of L-cate-
nin was increased. In conclusion, clozapine treatment
increased the amount of L-catenin, and induced its migration
into the nucleus.
4. Discussion
In these experiments, we found that clozapine is not cyto-
toxic up to a concentration of 10 WM, and may even have
neurotrophic e¡ects like the growth factors. In the serum-
starved cells the phosphorylations of Akt and GSK-3L were
reduced compared to the serum-stimulated condition. Cloza-
pine treatment restored the phosphorylation status of Akt and
its potential downstream molecule GSK-3L. These e¡ects of
clozapine on Akt and GSK-3 are also achieved by another
mood-stabilizing agent, valproate, whereas lithium, another
mood stabilizer, does not phosphorylate Akt but still phos-
phorylates GSK-3 [5]. Since GSK-3 can be phosphorylated by
multiple kinases, the upstream event may be di¡erent with
Fig. 2. Serum-starved (SS) SH-SY5Y cells were exposed to 10 WM
clozapine (Clo) for the indicated times and the cellular proteins
were analyzed by SDS^PAGE and Western blotting with anti-phos-
pho-GSK-3L (Ser9, Tyr216), and anti-L-actin antibodies. In certain
conditions, the phospho-GSK-3L antibody detected two separate
bands. According to the manufacturer’s guidelines, the upper band
is probably phosphorylated at another site of GSK-3L as well.
Fig. 3. Serum-starved (SS) SH-SY5Y cells were exposed to 10 WM
clozapine (Clo) for the indicated times and the cellular proteins
were analyzed by SDS^PAGE and Western blotting with anti-phos-
pho-Akt (A) and anti-Dvl (B).
Fig. 4. Serum-starved (SS) SH-SY5Y cells were pretreated with 20
WM LY294002 (LY) for 1 h and exposed to 10 WM clozapine (Clo)
for 1 h and 3 h in the presence of the inhibitors and the cellular
proteins were analyzed by SDS^PAGE and Western blotting with
antibodies to anti-phospho-GSK-3L, anti-phospho-Akt, and anti-
Dvl. Serum-starved SH-SY5Y cells were exposed to 10 WM cloza-
pine for 3 h, and extracts lysates were treated with 50 U of alkaline
phosphatase (A.P.) (Sigma) at 30‡C for 30 min, and the cellular
proteins were analyzed by SDS^PAGE and Western blotting with
antibodies to phospho-GSK-3L, phospho-Akt and Dvl.
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di¡erent stimuli [14,15]. In cerebellar granule cells, it was re-
ported that lithium does phosphorylate Akt [16]. So, di¡er-
ences in the systems should also be considered. Although the
upstream event of Akt phosphorylation was not elucidated,
the e¡ect of clozapine is thought to be mediated by PI3K
activation since a PI3K inhibitor abolished Akt activation,
just as is the case with valproate. This activation of Akt
and GSK-3 demonstrates that there may be similarities in
the mechanism of action between valproate and clozapine.
However, when the phosphorylation-activation of Akt was
blocked, the phosphorylation of GSK-3 was not a¡ected. This
suggested the activation of another Akt-independent mecha-
nism for GSK-3 phosphorylation with clozapine treatment. In
this aspect, clozapine showed similarity to lithium. One pos-
sible explanation was the activation of Wnt-mediated signal-
ing [17]. And indeed, this seems to be the case, since the phos-
phorylation of Dvl [11] was increased after clozapine
treatment. The mobility-shifted signal appears to be the phos-
phorylated Dvl band since in vitro treatment of cell culture
lysates with alkaline phosphatase abolished the shifted signal,
along with other phospho-protein signals. Although treatment
with a speci¢c inhibitor in this pathway was not available, the
hypothesis that the activation of Wnt-mediated signaling may
increase the phosphorylation of GSK-3 was also supported by
the fact that the downstream molecule in this pathway was
a¡ected by clozapine treatment. Clozapine increased the
amount of L-catenin in whole cell lysates. Dephosphorylation
of GSK-3 leads to phosphorylation of L-catenin [18], after
which the phosphorylated L-catenin is degraded. Therefore,
the reduction of GSK-3 activity by Ser9 phosphorylation in
this pathway results in the increase in L-catenin. Moreover, as
a transcription factor, L-catenin is mobilized into the nucleus
by Wnt signaling. Nuclear migration of L-catenin was evident
after clozapine treatment. These data clearly show that cloza-
pine activates the Dvl-mediated GSK-3 phosphorylation. The
role of Wnt-mediated signaling in the mature organism is not
clear, but may also be related to cell survival just as the PI3K-
Akt pathway [19]. So clozapine has dual action on GSK-3
phosphorylation. First it activates Akt, probably via the acti-
vation of PI3K. This pathway was similar to serum- or
growth factor-mediated signaling. Second, it activates Dvl,
probably via the Wnt-Frizzled pathway. It is not certain
which one is more important. However, it should be noted
that the blocking of the PI3K-Akt pathway did not in£uence
the survival of cells. We have demonstrated that the Wnt
pathway transcription factor L-catenin is regulated by cloza-
pine. NF-UB, a representative survival factor activated by the
PI3K-Akt pathway, has also been reported to be activated by
Wnt signaling in PC12 cells [20].
In conclusion, clozapine has neurotrophic action and acti-
vates both Akt-mediated and Dvl-mediated signaling. But the
latter seems to have more important e¡ects on the phosphor-
ylation of GSK-3. Clozapine also increased the total cellular
and intranuclear level of L-catenin, at concentrations not
much higher than the therapeutic concentration. It is neces-
sary to further investigate whether this e¡ect is speci¢c to
clozapine or also applies to other antipsychotics and neuro-
trophic medications.
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